PHS
CATX icon

Pekin Hardy Strauss’s Perspective Therapeutics CATX Stock Holding History

Pekin Hardy Strauss’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1K Hold
10,000
– – ﹤0.01% 506
2026
Q1 		$41.7K Buy
+10,000
New +$42.2K ﹤0.01% 472

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Pekin Hardy Strauss's CATX Position: Q2 2026 in Review

Pekin Hardy Strauss held its Perspective Therapeutics (CATX) position steady in Q2 2026 at 10,000 shares worth $34.1K. The position accounts for ﹤0.01% of the portfolio, ranked #506.

Pekin Hardy Strauss first reported a position in CATX in Q1 2026 and has held it in 2 quarters since. The position peaked at $41.7K in Q1 2026. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Pekin Hardy Strauss held 10,000 shares of Perspective Therapeutics worth $34.1K as of Q2 2026.
  • Pekin Hardy Strauss left its Perspective Therapeutics share count unchanged in Q2 2026.
  • Perspective Therapeutics made up ﹤0.01% of Pekin Hardy Strauss's portfolio in Q2 2026, its #506 holding.
  • Pekin Hardy Strauss first reported a position in Perspective Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Pekin Hardy Strauss's Perspective Therapeutics position peaked at $41.7K in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Pekin Hardy Strauss's 13F filing for Q2 2026, filed 30 Jul 2026.